$REVB News

Last published 1w ago

1w agoREVBREVELATION BIOSCIENCES, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
3w agoREVBRevelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026Business WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today
2mo agoREVBRevelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN StudyBusiness Wire– Study on track to begin later this year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to treat
3mo agoREVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026ACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to
3mo agoREVBIndependent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney InjuryACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / August 3, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to
3mo agoREVBRevelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)ACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / July 21, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to
4mo agoREVBRevelation Biosciences Announces Adoption of Stockholder Rights PlanACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / July 10, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to
5mo agoREVBRevelation Biosciences Expands Acute Kidney Injury Advisory BoardACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to treat acute and
6mo agoREVBRevelation Biosciences, Inc. Releases Corporate Update Letter to StockholdersACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to treat acute and
6mo agoREVBRevelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026ACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to treat acute and
7mo agoREVBRevelation Biosciences Announces Formation of Acute Kidney Injury Advisory BoardACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company developing innovative solutions to treat acute and
7mo agoREVBRevelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical StudyACCESS Newswire- A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence -SAN DIEGO, CA / ACCESS Newswire / March 30,
7mo agoREVBREMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing inflammation to optimize
7mo agoREVBRevelation Biosciences to Host Fireside Chat at 38th Annual Roth ConferenceACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing inflammation to optimize
8mo agoREVBRevelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025ACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing inflammation to optimize
10mo agoREVBRevelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)ACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / January 12, 2026 / Revelation Biosciences, Inc. , a clinical-stage life sciences company that is focused on rebalancing inflammation, today
11mo agoREVBRevelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special MeetingACCESS NewswireSAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing
11mo agoREVBRevelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This YearACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / November 20, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company that is focused on rebalancing
1y agoREVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025ACCESS NewswireSAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company that is focused on
1y agoREVBRevelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record DateACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / October 29, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing
1y agoREVBRevelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025ACCESS NewswireSAN DIEGO, CA, CA / ACCESS Newswire / October 15, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing
1y agoREVBRevelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross ProceedsACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing
1y agoREVBRevelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical DataACCESS Newswire- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data discussion
1y agoREVBReminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line DataACCESS NewswireSAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. , a clinical-stage life sciences company focused on rebalancing
1y agoREVBRevelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical StudyACCESS Newswire- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients -- Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease -Data discussion
1y agoREVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025Business WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for
1y agoREVBRevelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and ResearchBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) the "Company" or "Revelation") a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today congratulates its former chairman and
1y agoREVBRevelation Biosciences Inc. Completes Dosing of Patients in PRIME StudyBusiness Wire– Sample analysis and data collection ongoing – – Data expected during Q3 2025 – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on
1y agoREVBRevelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025Business WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special
1y agoREVBRevelation Biosciences, Inc. Announces Closing of $4 Million Public OfferingBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the closing of its
1y agoREVBRevelation Biosciences, Inc. Announces Pricing of $4 Million Public OfferingBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public
1y agoREVBRevelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of DirectorsBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced the retirement of George F.
1y agoREVBRevelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025Business WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three months ended
1y agoREVBRevelation Biosciences to Develop Gemini for Infection in Severe Burn PatientsBusiness Wire- This new indication is another step to unlock the full potential of the Gemini Platform - Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is
1y agoREVBGemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear CellsBusiness Wire– Observed response is excellent surrogate of the potential of Gemini in target indications – – Equivalent response anticipated in Phase 1b study CKD patients – Revelation Biosciences, Inc. (NASDAQ:REVB) (the
1y agoREVBRevelation Biosciences to Host Fireside Chat at 37th Annual Roth ConferenceBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke
1y agoREVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024Business WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve
1y agoREVBRevelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD PatientsBusiness Wire– Topline data expected Mid-Year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health,
1y agoREVBRevelation Biosciences, Inc. Receives Continued NASDAQ Listing ApprovalBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today the Nasdaq Stock Market
1y agoREVBRevelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025Business WireRevelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2025, the Company will implement a 1-for-16 reverse split of its common stock following approval at its
1y agoREVBRevelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD PatientsBusiness Wire– Dosing to Commence Mid-February – – Topline data expected Mid-Year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing
1y agoREVBRevelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025Business Wire– A vote for Proposal 2 saves the Company over $200,000 per year – Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the
1y agoREVBNasdaq Grants Revelation Biosciences Inc. Continued ListingBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced
1y agoREVBRevelation Biosciences Inc. Announces Exercise of Warrants for $4 Million in Gross ProceedsBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the treatment of disease, announced
1y agoREVBRevelation Biosciences Inc. Announces FDA Acceptance of Gemini INDBusiness Wire-Phase 1b Study in CKD Patients to begin early 2025- Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of
2y agoREVBRevelation Biosciences, Inc. Completes the GMP Manufacture of Gemini Clinical Drug SupplyBusiness WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease,
2y agoREVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2024Business WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by
2y agoREVBRevelation Biosciences' Gemini Induces Dose Dependent Significant Increases in IL-10Business WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease,
2y agoREVBRevelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross ProceedsBusiness WireRevelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today
2y agoREVBRevelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024Business WireRevelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and treatment of disease by